Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: A systematic literature review

International Journal of Rheumatology

Volumn 2013, Issue , 2013, Pages

  Oglesby, A ^a   Shaul, A J ^b   Pokora, T ^b   Paramore, C ^b   Cragin, L ^b   Dennis, G ^a   Narayanan, S ^a   Weinstein, A ^c  

^a GLAXOSMITHKLINE   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO;

ALOPECIA; AMENORRHEA; ANEMIA; BLOOD TOXICITY; CYTOPENIA; DRUG COST; DRUG FATALITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; MENTAL DISEASE; MOOD DISORDER; OBSERVATIONAL STUDY; OVARY DISEASE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84877270440     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2013/347520     Document Type: Review

References (65)

1. Childs S. G., The pathogenesis of systemic lupus erythematosus. Orthopaedic Nursing 2006 25 2 140 145
2. Cooper G. S., Dooley M. A., Treadwell E. L., St Clair E. W., Parks C. G., Gilkeson G. S., Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis & Rheumatism 1998 41 10 1714 1724 (Pubitemid 28465525)
3. Panopalis P., Clarke A. E., Systemic lupus erythematosus: clinical manifestations, treatment and economics. Expert Review of Pharmacoeconomics and Outcomes Research 2006 6 5 563 575 2-s2.0-33751011062 10.1586/14737167.6.5.563 (Pubitemid 44741606)
4. D'Cruz D. P., Khamashta M. A., Hughes G. R., Systemic lupus erythematosus. The Lancet 2007 369 9561 587 596 2-s2.0-33846897631 10.1016/S0140-6736(07)60279-7 (Pubitemid 46241445)
5. Kalunian K., Joan T. M., New directions in the treatment of systemic lupus erythematosus. Current Medical Research & Opinion 2009 25 6 1501 1514
6. Yildirim-Toruner C., Diamond B., Current and novel therapeutics in the treatment of systemic lupus erythematosus. Journal of Allergy and Clinical Immunology 2011 127 2 303 312
7. Furie R., Stohl W., Ginzler E. M., Becker M., Mishra N., Chatham W., Merrill J. T., Weinstein A., Joseph W. J., Zhong J., Cai W., Freimuth W., Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Research and Therapy 2008 10 5, article R109 2-s2.0-54349100000 10.1186/ar2506
8. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis & Rheumatism 1999 42 9 1785 1796
9. Moore R. A., Derry S., Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Research and Therapy 2006 8, article R182 2-s2.0-33847193118 10.1186/ar2093
10. Kamanamool N., McEvoy M., Attia J., Ingsathit A., Ngamjanyaporn P., Thakkinstian A., Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine 2010 89 4 227 235 2-s2.0-77954719024 10.1097/MD.0b013e3181e93d00
11. Lee Y. H., Woo J. H., Choi S. J., Ji J. D., Song G. G., Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 2010 19 6 703 710 2-s2.0-77950204511 10.1177/0961203309357763
12. Touma Z., Gladman D. D., Urowitz M. B., Beyene J., Uleryk E. M., Shah P. S., Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. Journal of Rheumatology 2011 38 1 69 78 2-s2.0-78650881053 10.3899/jrheum.100130
13. Schmajuk G., Yazdany J., Drug monitoring in systemic lupus erythematosus: a systematic review. Seminars in Arthritis and Rheumatism 2011 40 6 559 575
14. Swan J. T., Riche D. M., Riche K. D., Majithia V., Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis. Journal of Investigative Medicine 2011 59 2 246 258 2-s2.0-79953873181 10.231/JIM.0b013e318204c965
15. Touma Z., Urowitz M., Gladman D., Systematic review and meta-analysis of randomized trials for mycophenolic acid and mycophenolate mofetil for induction treatment of lupus nephritis. Journal of Rheumatology 2010 37 6 1310 1311 2-s2.0-78650881053
16. Sarnes E., Crofford L., Watson M., Dennis G., Kan H., Bass D., Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clinical Therapeutics 2011 33 10 1413 1432
17. Appel G. B., Contreras G., Dooley M. A., Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Journal of the American Society of Nephrology 2009 20 5 1103 1112
18. Chan T. M., Tse K. C., Tang C. S., Mok M. Y., Li F. K., Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. Journal of the American Society of Nephrology 2005 16 4 1076 1084 (Pubitemid 41710318)
19. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., Roth D., Sequential therapies for proliferative lupus nephritis. The New England Journal of Medicine 2004 350 10 971 980 2-s2.0-1442355581 10.1056/NEJMoa031855 (Pubitemid 38269274)
20. Contreras G., Tozman E., Nahar N., Metz D., Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005 14 3, supplement 1 S33 S38 2-s2.0-16244382368 (Pubitemid 40460514)
21. Cortés-Hernández J., Torres-Salido M. T., Medrano A. S., Tarrés M. V., Ordi-Ros J., Long-term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrology Dialysis Transplantation 2010 25 12 3939 3948 2-s2.0-78649517139 10.1093/ndt/gfq322
22. Ginzler E. M., Dooley M. A., Aranow C., Kim M. Y., Buyon J., Merrill J. T., Petri M., Gilkeson G. S., Wallace D. J., Weisman M. H., Appel G. B., Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. The New England Journal of Medicine 2005 353 21 2219 2228 2-s2.0-28144433147 10.1056/NEJMoa043731 (Pubitemid 41697285)
23. Houssiau F. A., Vasconcelos C., D'Cruz D., Sebastiani G. D., De Ramon Garrido E., Danieli M. G., Abramovicz D., Blockmans D., Cauli A., Direskeneli H., Galeazzi M., Gül A., Levy Y., Petera P., Popovic R., Petrovic R., Sinico R. A., Cattaneo R., Font J., Depresseux G., Cosyns J. P., Cervera R., The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Annals of the Rheumatic Diseases 2010 69 1 61 64 2-s2.0-73449086703 10.1136/ard.2008.102533
24. Isenberg D., Appel G. B., Contreras G., Dooley M. A., Ginzler E. M., Jayne D., Sánchez-Guerrero J., Wofsy D., Yu X., Solomons N., Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 2010 49 1 128 140 2-s2.0-77349120902
25. Lu F., Tu Y., Peng X., Wang L., Wang H., Sun Z., Zheng H., Hu Z., A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 2008 17 7 622 629 2-s2.0-48249117559 10.1177/0961203308089428
26. Pisoni C. N., Sanchez F. J., Karim Y., Cuadrado M. J., D'Cruz D. P., Abbs I. C., Khamashta M. A., Hughes G. R. V., Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. Journal of Rheumatology 2005 32 6 1047 1052 2-s2.0-20444494317 (Pubitemid 40828077)
27. Riskalla M. M., Somers E. C., Fatica R. A., McCune W. J., Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. Journal of Rheumatology 2003 30 7 1508 1512 2-s2.0-0037829132 (Pubitemid 36835447)
28. Tang Z., Yang G., Yu C., Yu Y., Wang J., Hu W., Zeng C., Chen H., Liu Z., Li L., Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology 2008 13 8 702 707 2-s2.0-58149107325 10.1111/j.1440-1797. 2008.00975.x
29. Fortin P. R., Abrahamowicz M., Ferland D., Lacaille D., Smith C. D., Zummer M., Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Care and Research 2008 59 12 1796 1804 2-s2.0-57149118480 10.1002/art.24068
30. McDermott E. M., Powell R. J., Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Annals of the Rheumatic Diseases 1996 55 4 224 229 2-s2.0-0029968720 (Pubitemid 26122247)
31. Austin H. A., Klippel J. H., Balow J. E., Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. The New England Journal of Medicine 1986 314 10 614 619 (Pubitemid 16132725)
32. Carette S., Klippel J. H., Decker J. L., Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Annals of Internal Medicine 1983 99 1 1 8 (Pubitemid 13066648)
33. Griffiths B., Emery P., Ryan V., Isenberg D., Akil M., Thompson R., Maddison P., Griffiths I. D., Lorenzi A., Miles S., Situnayake D., Teh L. S., Plant M., Hallengren C., Nived O., Sturfelt G., Chakravarty K., Tait T., Gordon C., The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology 2010 49 4 723 732 2-s2.0-77955730184
34. Moroni G., Doria A., Mosca M., Alberighi O. D., Ferraccioli G., Todesco S., Manno C., Altieri P., Ferrara R., Greco S., Ponticelli C., A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clinical Journal of the American Society of Nephrology 2006 1 5 925 932 2-s2.0-34548454046 10.2215/CJN.02271205
35. Naughton M. A., Battaglia E., O'Brien S., Walport M. J., Botto M., Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999 38 7 640 644 2-s2.0-0032732591 10.1093/rheumatology/38.7.640 (Pubitemid 29507333)
36. Mok C. C., Lau C. S., Wong R. W. S., Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis & Rheumatism 1998 41 5 831 837 (Pubitemid 28225783)
37. Chen W., Tang X., Liu Q., Chen W., Fu P., Liu F., Liao Y., Yang Z., Zhang J., Chen J., Lou T., Fu J., Kong Y., Liu Z., Fan A., Rao S., Li Z., Yu X., Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. American Journal of Kidney Diseases 2011 57 2 235 244 2-s2.0-78751610590 10.1053/j.ajkd.2010.08.036
38. Gourley M. F., Austin H. A., Scott D., Yarboro C. H., Vaughan E. M., Muir J., Boumpas D. T., Klippel J. H., Balow J. E., Steinberg A. D., Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Annals of Internal Medicine 1996 125 7 549 557 2-s2.0-0030268581 (Pubitemid 126450087)
39. Houssiau F. A., Vasconcelos C., D'Cruz D., Sebastiani G. D., De Ramon Garrido E., Danieli M. G., Abramovicz D., Blockmans D., Mathieu A., Direskeneli H., Galeazzi M., Gül A., Levy Y., Petera P., Popovic R., Petrovic R., Sinico R. A., Cattaneo R., Font J., Depresseux G., Cosyns J. P., Cervera R., Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis and Rheumatism 2002 46 8 2121 2131 2-s2.0-0036673864 10.1002/art.10461
40. Illei G. G., Austin H. A., Crane M., Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Annals of Internal Medicine 2001 135 4 248 257 (Pubitemid 32799338)
41. Ioannidis J. P. A., Katsifis G. E., Tzioufas A. G., Moutsopoulos H. M., Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. Journal of Rheumatology 2002 29 10 2129 2135 2-s2.0-0036791907
42. Liang L., Yang X., Xu H., Zhan Z., Ye Y., Yu X., Chen W., Clinical predictors of recovery and complications in the management of recent-onset renal failure in lupus nephritis: a Chinese experience. Journal of Rheumatology 2004 31 4 701 706 2-s2.0-1842530454 (Pubitemid 38451255)
43. Manger K., Wildt L., Kalden J. R., Manger B., Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmunity Reviews 2006 5 4 269 272 2-s2.0-33746910250 10.1016/j.autrev.2005. 10.001 (Pubitemid 44269020)
44. Mok C. C., Ying K. Y., Ng W. L., Lee K. W., To C. H., Lau C. S., Wong R. W. S., Au T. C., Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. American Journal of Medicine 2006 119 4 355.e25 355.e33 2-s2.0-33645241849 10.1016/j.amjmed.2005.08.045
45. Pryor B. D., Bologna S. G., Kahl L. E., Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis and Rheumatism 1996 39 9 1475 1482 2-s2.0-0029788602 (Pubitemid 26314980)
46. Seong S. S., Choi C. B., Yun H. R., Kim Y. J., Sung Y. K., Bae S. C., Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis. Rheumatology International 2008 28 5 453 458 2-s2.0-43049106151 10.1007/s00296-007-0464-9 (Pubitemid 351629483)
47. Takada K., Arefayene M., Desta Z., Yarboro C. H., Boumpas D. T., Balow J. E., Flockhart D. A., Illei G. G., Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis and Rheumatism 2004 50 7 2202 2210 2-s2.0-3142760835 10.1002/art.20338 (Pubitemid 38924398)
48. Urowitz M. B., Ibañez D., Ali Y., Gladman D. D., Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide. Journal of Rheumatology 2007 34 7 1491 1496 2-s2.0-34447518980 (Pubitemid 47067984)
49. Velásquez X., Verdejo U., Massardo L., Martínez M. E., Arriagada S., Rosenberg H., Valdivieso A., Jacobelli S., Outcome of Chilean patients with lupus nephritis and response to intravenous cyclophosphamide. Journal of Clinical Rheumatology 2003 9 1 7 14 2-s2.0-0037331088 10.1097/01.RHU.0000049711.14038.9F (Pubitemid 36262699)
50. Wang H. Y., Cui T. G., Hou F. F., Ni Z. H., Chen X. M., Lu F. M., Xu F. F., Yu X. Q., Zhang F. S., Zhao X. Z., Zhao M. H., Wang G. B., Qian J. Q., Cai G. Y., Zhu T. Y., Wang Y. H., Jiang Z. P., Li Y. N., Mei C. L., Zou W. Z., Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008 17 7 638 644 2-s2.0-48249119614 10.1177/0961203308089408
51. Conti F., Priori R., Alessandri C., Spinelli F. R., Medda E., Valesini G., Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A. Lupus 2000 9 9 676 680 2-s2.0-0034534077 10.1191/096120300676096627 (Pubitemid 32011793)
52. Chan T. M., Tse K. C., Tang C. S. O., Mok M. Y., Li F. K., Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. Journal of the American Society of Nephrology 2005 16 4 1076 1084 2-s2.0-20444466207 10.1681/ASN.2004080686 (Pubitemid 41710318)
53. Kipen Y., Littlejohn G. O., Morand E. F., Methotrexate use in systemic lupus erythematosus. Lupus 1997 6 4 385 389 2-s2.0-0030996043 (Pubitemid 27232133)
54. Rahman P., Humphret-Murto S., Gladman D. D., Urowitz M. B., Cytotoxic therapy in systemic lupus erythematosus: experience from a single center. Medicine 1997 76 6 432 437 2-s2.0-0031456991 10.1097/00005792-199711000-00006 (Pubitemid 28016539)
55. Goldblatt F., Chambers S., Rahman A., Isenberg D. A., Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009 18 8 682 689 2-s2.0-67049167424 10.1177/0961203308101019
56. Zhu B., Chen N., Lin Y., Ren H., Zhang W., Wang W. M., Pan X. X., Yu H. J., Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrology Dialysis Transplantation 2007 22 7 1933 1942 2-s2.0-34547830199 10.1093/ndt/gfm066 (Pubitemid 47244763)
57. Walsh M., Jayne D., Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney International 2007 72 6 676 682 2-s2.0-34548492958 10.1038/sj.ki.5002395 (Pubitemid 47373785)
58. Mok C. C., Ying K. Y., Yim C. W., Ng W. L., Wong W. S., Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus 2009 18 12 1091 1095 2-s2.0-70349512793 10.1177/ 0961203309106602
59. Dooley M. A., Jayne D., Ginzler E. M., Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. The New England Journal of Medicine 2011 365 20 1886 1895
60. Gayed M., Bernatsky S., Ramsey-Goldman R., Clarke A. E., Gordon C., Lupus and cancer. Lupus 2009 18 6 479 485 2-s2.0-65149101308 10.1177/0961203309102556
61. Gladman D. D., Hussain F., Ibañez D., Urowitz M. B., The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002 11 4 234 239 2-s2.0-0036250262 10.1191/0961203302lu170oa (Pubitemid 34506728)
62. Noël V., Lortholary O., Casassus P., Cohen P., Géné reau T., André M. H., Mouthon L., Guillevin L., Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Annals of the Rheumatic Diseases 2001 60 12 1141 1144 2-s2.0-0035191827 10.1136/ard.60.12.1141 (Pubitemid 33096079)
63. Pani A., Standard immunosuppresive therapy of immune-mediated glomerular diseases. Autoimmunity Reviews 2012 10.1016/j.autrev.2012.11.012
64. Roccatello D., Novel diagnostic approaches and cost-benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease. Autoimmunity Reviews 2012 10.1016/j.autrev.2012.11.002
65. Leardini G., Rigon C., The impact of the profile of biologics on treatment costs. Autoimmunity Reviews 2012 10.1016/j.autrev.2012.11.011